HOXB4-transduced embryonic stem cell-derived Lin-c-kit + and Lin-Sca-1+ hematopoietic progenitors express H60 and are targeted by NK cells

Journal of Immunology

Volumn 183, Issue 9, 2009, Pages 5449-5457

  Tabayoyong, William B ^a   Salas, Juan G ^a   Bonde, Sabrina ^a   Zavazava, Nicholas ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; H60 PROTEIN; HOX PROTEIN; HOXB4 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; RAG2 PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MOTION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOLYSIS; EMBRYO; EMBRYONIC STEM CELL; ENGRAFTMENT; HEMATOPOIETIC STEM CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIGENS, DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EMBRYONIC STEM CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEODOMAIN PROTEINS; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINOR HISTOCOMPATIBILITY ANTIGENS; PROTO-ONCOGENE PROTEINS C-KIT; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC;

EID: 77954152195     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901807     Document Type: Article

References (39)

1. Itskovitz-Eldor, J., M. Schuldiner, D. Karsenti, A. Eden, O. Yanuka, M. Amit, H. Soreq, and N. Benvenisty. 2000. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 6: 88-95.
2. Williams, R. L., D. J. Hilton, S. Pease, T. A. Willson, C. L. Stewart, D. P. Gearing, E. F. Wagner, D. Metcalf, N. A. Nicola, and N. M. Gough. 1988. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336: 684-687.
3. Reubinoff, B. E., P. Itsykson, T. Turetsky, M. F. Pera, E. Reinhartz, A. Itzik, and T. Ben-Hur. 2001. Neural progenitors from human embryonic stem cells. Nat. Biotechnol. 19: 1134-1140.
4. Kehat, I., D. Kenyagin-Karsenti, M. Snir, H. Segev, M. Amit, A. Gepstein, E. Livne, O. Binah, J. Itskovitz-Eldor, and L. Gepstein. 2001. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108: 407-414.
5. Levenberg, S., J. S. Golub, M. Amit, J. Itskovitz-Eldor, and R. Langer. 2002. Endothelial cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 99: 4391-4396.
6. Kaufman, D. S., E. T. Hanson, R. L. Lewis, R. Auerbach, and J. A. Thomson. 2001. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 98: 10716-10721.
7. Pilat, S., S. Carotta, B. Schiedlmeier, K. Kamino, A. Mairhofer, E. Will, U. Modlich, P. Steinlein, W. Ostertag, C. Baum, et al. 2005. HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc. Natl. Acad. Sci. USA 102: 12101-12106.
8. Chan, K. M., S. Bonde, H. Klump, and N. Zavazava. 2008. Hematopoiesis and immunity of HOXB4-transduced embryonic stem cell-derived hematopoietic progenitor cells. Blood 111: 2953-2961.
9. Fandrich, F., X. Lin, G. X. Chai, M. Schulze, D. Ganten, M. Bader, J. Holle, D. S. Huang, R. Parwaresch, N. Zavazava, and B. Binas. 2002. Preimplantationstage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat. Med. 8: 171-178.
10. Drukker, M., G. Katz, A. Urbach, M. Schuldiner, G. Markel, J. Itskovitz-Eldor, B. Reubinoff, O. Mandelboim, and N. Benvenisty. 2002. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl. Acad. Sci. USA 99: 9864-9869.
11. Li, L., M. L. Baroja, A. Majumdar, K. Chadwick, A. Rouleau, L. Gallacher, I. Ferber, J. Lebkowski, T. Martin, J. Madrenas, and M. Bhatia. 2004. Human embryonic stem cells possess immune-privileged properties. Stem Cells 22: 448-456. (Pubitemid 39014562)
12. Drukker, M., H. Katchman, G. Katz, F. S. Even-Tov, E. Shezen, E. Hornstein, O. Mandelboim, Y. Reisner, and N. Benvenisty. 2006. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24: 221-229.
13. Bonde, S., and N. Zavazava. 2006. Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 24: 2192-2201.
14. Robertson, N. J., F. A. Brook, R. L. Gardner, S. P. Cobbold, H. Waldmann, and P. J. Fairchild. 2007. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc. Natl. Acad. Sci. USA 104: 20920-20925.
15. Kofidis, T., J. L. deBruin, M. Tanaka, M. Zwierzchoniewska, I. Weissman, E. Fedoseyeva, A. Haverich, and R. C. Robbins. 2005. They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur. J. Cardiothorac. Surg. 28: 461-466.
16. Swijnenburg, R. J., M. Tanaka, H. Vogel, J. Baker, T. Kofidis, F. Gunawan, D. R. Lebl, A. D. Caffarelli, J. L. de Bruin, E. V. Fedoseyeva, and R. C. Robbins. 2005. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112: I166-I172.
17. Diefenbach, A., A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1: 119-126.
18. Cerwenka, A., A. B. Bakker, T. McClanahan, J. Wagner, J. Wu, J. H. Phillips, and L. L. Lanier. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12: 721-727.
19. Carayannopoulos, L. N., O. V. Naidenko, D. H. Fremont, and W. M. Yokoyama. 2002. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169: 4079-4083.
20. Diefenbach, A., J. K. Hsia, M. Y. Hsiung, and D. H. Raulet. 2003. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur. J. Immunol. 33: 381-391.
21. Cao, X., E. W. Shores, J. Hu-Li, M. R. Anver, B. L. Kelsall, S. M. Russell, J. Drago, M. Noguchi, A. Grinberg, E. T. Bloom, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2: 223-238.
22. Fehniger, T. A., S. F. Cai, X. Cao, A. J. Bredemeyer, R. M. Presti, A. R. French, and T. J. Ley. 2007. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26: 798-811.
23. Huang, Y., F. Rezzoug, H. Xu, P. M. Chilton, C. L. Schanie, I. Fugier-Vivier, and S. T. Ildstad. 2005. NK cells play a critical role in the regulation of class I-deficient hemopoietic stem cell engraftment: evidence for NK tolerance correlates with receptor editing. J. Immunol. 175: 3753-3761.
24. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171: 27-31.
25. Westerhuis, G., W. G. Maas, R. Willemze, R. E. Toes, and W. E. Fibbe. 2005. Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood 106: 2215-2220.
26. Hamby, K., A. Trexler, T. C. Pearson, C. P. Larsen, M. R. Rigby, and L. S. Kean. 2007. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism. Am. J. Transplant. 7: 1884-1896.
27. Lecoeur, H., M. Fevrier, S. Garcia, Y. Riviere, and M. L. Gougeon. 2001. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 253: 177-187.
28. Barao, I., and W. J. Murphy. 2003. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol. Blood Marrow Transplant. 9: 727-741.
29. Chiang, E. Y., M. Henson, and I. Stroynowski. 2002. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis. J. Immunol. 168: 2200-2211.
30. Bonde, S., K. M. Chan, and N. Zavazava. 2008. ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS ONE 3: e3212.
31. Murphy, W. J., V. Kumar, and M. Bennett. 1987. Acute rejection of murine bone marrow allografts by natural killer cells and T cells: differences in kinetics and target antigens recognized. J. Exp. Med. 166: 1499-1509.
32. Tian, X., P. S. Woll, J. K. Morris, J. L. Linehan, and D. S. Kaufman. 2006. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 24: 1370-1380. (Pubitemid 44464705)
33. Ladhoff, J., M. Bader, S. Brosel, E. Effenberger, D. Westermann, H. D. Volk, and M. Seifert. 2009. Low immunogenicity of endothelial derivatives from rat embryonic stem cell-like cells. Cell Res. 19: 507-518.
34. Mammolenti, M., S. Gajavelli, P. Tsoulfas, and R. Levy. 2004. Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro. Stem Cells 22: 1101-1110. (Pubitemid 39507095)
35. Bhattacharya, D., D. J. Rossi, D. Bryder, and I. L. Weissman. 2006. Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning. J. Exp. Med. 203: 73-85.
36. Kyba, M., R. C. Perlingeiro, and G. Q. Daley. 2002. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 109: 29-37.
37. Vilches, C., and P. Parham. 2006. Do NK-cell receptors and alloreactivity affect solid organ transplantation? Transpl. Immunol. 17: 27-30.
38. Kroemer, A., X. Xiao, N. Degauque, K. Edtinger, H. Wei, G. Demirci, and X. C. Li. 2008. The innate NK cells, allograft rejection, and a key role for IL-15. J. Immunol. 180: 7818-7826.
39. Wu, D., A. S. Boyd, and K. J. Wood. 2008. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege, but still represent novel targets of immune attack. Stem Cells 26: 1939-1950.